Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...

Abbott has taken a step forward in the development of a new addition to its structural heart portfolio, completing the first ...

Advantage Therapeutics is spinning off some of its age-related disease R&D into a new company called Klothea Bio. | Klothea ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

To recruit volunteers more quickly for clinical trials, a team of National Institutes of Health (NIH) researchers has turned ...

Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) ...

The annual Fierce 50 Gala is set to shine a spotlight on the life sciences industry's most transformative leaders, ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high ...

Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...